Epidermal Growth Factor Receptor as a Therapeutic Target in Lung Cancer

Joan H. Schiller

doi:10.1055/s-2004-829640

Subscribe to RSS

Please copy the URL and add it into your RSS Feed Reader.

https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000075.xml

Share / Bookmark

Facebook X Linkedin Weibo

Download PDF

Semin Respir Crit Care Med 2004; 25: 11-16
DOI: 10.1055/s-2004-829640

Epidermal Growth Factor Receptor as a Therapeutic Target in Lung Cancer

Joan H. Schiller¹

¹Comprehensive Cancer Center, University of Wisconsin Hospital and Clinics, Madison, Wisconsin

Further Information

Publication History

Publication Date:
22 June 2004 (online)

Abstract
Full Text
References

Buy Article Permissions and Reprints

Almost two decades of research to determine how cancer cells differ from noncancerous cells at the molecular level have been richly rewarding. Several molecular growth factors and receptors have been discovered that play a role in tumor development and are differentially expressed in tumor cells. In this regard, the structure and function of the epidermal growth factor receptor (EGFR) have been characterized. Efforts to develop effective anticancer therapy have targeted this receptor because it is critical to tumor cell proliferation, survival, and invasiveness. Overexpression of EGFR occurs in several epithelial cell tumors, including non-small cell lung cancer (NSCLC). Small-molecular-weight EGFR tyrosine kinase inhibitors and EGFR monoclonal antibodies are among the agents that have demonstrated activity against NSCLC. These compounds, which are designed to selectively target tumor cells, represent a new and novel treatment approach that is being evaluated in NSCLC clinical trials.

KEYWORDS

Epidermal growth factor receptor (EGFR) - tyrosine kinase - non-small cell lung cancer (NSCLC) - ZD1839 - IMC-C225

REFERENCES

1 American Cancer Society .Cancer Facts and Figures, 2003. Atlanta, GA; American Cancer Society 2003

Search in Google Scholar
2 Pisters K M. Adjuvant and neoadjuvant therapy for early stage non-small cell lung cancer. Semin Oncol. 2001; 28(suppl 14) S23-S28

Crossref PubMed Search in Google Scholar
3 Shepherd F A, Fossella F V, Lynch T et al.. Docetaxel (taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: a review of two phase III trials. Semin Oncol. 2001; 28(suppl 2) S4-S9

PubMed Search in Google Scholar
4 Chang A Y, Kim K, Glick J et al.. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: the Eastern Cooperative Oncology Group results. J Natl Cancer Inst. 1993; 85 388-394

PubMed Search in Google Scholar
5 Roszkowski K, Pluzanska A, Krzakowski M et al.. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naïve patients with metastatic or nonresectable localized non-small cell lung cancer (NSCLC). Lung Cancer. 2000; 27 145-157

Crossref PubMed Search in Google Scholar
6 Abratt R P, Bexwoda W R, Falkson G et al.. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol. 1994; 12 1535-1540

PubMed Search in Google Scholar
7 Depierre A, Lemarie E, Dabouis G et al.. A phase II study of navelbine (vinorelbine) in the treatment of non-small-cell lung cancer. Am J Clin Oncol. 1991; 14 115-119

PubMed Search in Google Scholar
8 Ranson M, Davidson N, Nicholson M et al.. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 2000; 92 1074-1080

Crossref PubMed Search in Google Scholar
9 Anderson H, Hopwood P, Stephens R J et al.. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer: a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br J Cancer. 2000; 83 447-453

Crossref PubMed Search in Google Scholar
10 Bunn Jr P A. Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why?. J Clin Oncol. 2002; 20 S23-S33

PubMed Search in Google Scholar
11 Herbst R S, Langer C J. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol. 2002; 29(suppl 4) S27-S36

PubMed Search in Google Scholar
12 Ethier S P. Signal transduction pathways: the molecular basis for targeted therapies. Semin Radiat Oncol. 2002; 12(suppl 2) S3-S10

Crossref PubMed Search in Google Scholar
13 Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene. 2000; 19 6550-6565

Crossref PubMed Search in Google Scholar
14 Ferreira C G, Huisman C, Giaccone G. Novel approaches to the treatment of non-small cell lung cancer. Crit Rev Oncol Hematol. 2002; 41 57-77

PubMed Search in Google Scholar
15 Chan T O, Rittenhouse S E, Tsichlis P N. AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation. Annu Rev Biochem. 1999; 68 965-1014

Crossref PubMed Search in Google Scholar
16 Engebraaten O, Bjerkvig R, Pedersen P H et al.. Effects of EGF, bFGF, NGF and PDGF (bb) on cell proliferative, migratory and invasive capacities of human brain-tumour biopsies in vitro. Int J Cancer. 1993; 53 209-214

Search in Google Scholar
17 Lammering G, Hewit T H, Hawkins W T et al.. Epidermal growth factor receptor as a genetic therapy target for carcinoma cell radiosensitization. J Natl Cancer Inst. 2001; 93 921-929

Crossref PubMed Search in Google Scholar
18 Fujino S, Enokibori T, Tezuka N et al.. A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer. Eur J Cancer. 1996; 32A 2070-2074

PubMed Search in Google Scholar
19 Salomon D S, Brandt R, Ciardiello F et al.. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995; 19 183-232

Crossref PubMed Search in Google Scholar
20 Veale D, Kerr N, Gibson G J et al.. The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. Br J Cancer. 1993; 68 162-165

PubMed Search in Google Scholar
21 Pavelic K, Banjac Z, Pavelic J et al.. Evidence for a role of EGF receptor in the progression of human lung carcinoma. Anticancer Res. 1993; 13 1133-1137

PubMed Search in Google Scholar
22 Swinson D E, Cox G, Jones J L et al.. Activated epidermal growth factor receptor (EGFR) correlates with a poor prognosis in non-small cell lung cancer (NSCLC) [abstract 1208]. Proc Am Soc Clin Oncol. 2002; 21 303a

PubMed Search in Google Scholar
23 Bowers G, Reardon D, Hewitt T et al.. The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells. Oncogene. 2001; 20 1388-1397

Crossref PubMed Search in Google Scholar
24 Herbst R S, Shin D M. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer. 2002; 94 1593-1611

Crossref PubMed Search in Google Scholar
25 Mendelsohn J, Dinney C P. The Willet F. Whitmore, Jr. Lectureship: blockade of epidermal growth factor receptors as anticancer therapy. J Urol. 2001; 165 1152-1157

PubMed Search in Google Scholar
26 Shin D M, Nemunaitis J, Zinner R G et al.. A phase I clinical and biomarker study of CI-1033, a novel pan-ErbB tyrosine kinase inhibitor in patients with solid tumors [abstract 324]. Proc Am Soc Clin Oncol. 2001; 20 82a

PubMed Search in Google Scholar
27 Wakeling A E, Barker A J, Davies D H et al.. Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines. Breast Cancer Res Treat. 1996; 38 67-73

Crossref PubMed Search in Google Scholar
28 Ciardiello F, Caputo R, Bianco R et al.. Antitumor effect and potential of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res. 2000; 6 2053-2063

PubMed Search in Google Scholar
29 Woodburn J R, Barker A J, Wakeline A E et al.. 6-amino-4 (3-methyl-phenylamino): an EGF receptor tyrosine kinase inhibitor with activity in a range of human tumor xenografts. Proc Am Assoc Cancer Res. 1996; 36 390

PubMed Search in Google Scholar
30 Woodburn J R, Barker A J, Gibson K H et al.. ZD 1839, an epidermal growth factor tyrosine kinase inhibitor selected for clinical development. Proc Am Assoc Cancer Res. 1997; 38 633

PubMed Search in Google Scholar
31 Albanell J, Rojo F, Averbuch S et al.. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol. 2002; 20 110-124

Crossref PubMed Search in Google Scholar
32 Raben D, Helfrich B A, Chan D et al.. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin Oncol. 2002; 29(suppl 4) S37-S46

Crossref PubMed Search in Google Scholar
33 Sirotnak F M, Zakowski M F, Miller V A et al.. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res. 2000; 6 4885-4892

PubMed Search in Google Scholar
34 Baselga J, Rischin D, Ranson M et al.. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol. 2002; 20 4292-4302

Crossref PubMed Search in Google Scholar
35 Kris M, Herbst R et al.. Objective regressions in non-small cell lung cancer patients treated in phase I trials of oral ZD 1839 (Iressa), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR). Lung Cancer. 2000; 29(suppl 1) S72

PubMed Search in Google Scholar
36 Kelly H, Ferry D et al.. ZD 1839 (Iressa) an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI): pharmacokinetics in a phase I study of patients with advanced cancer. Proc Am Assoc Cancer Res. 2000; 41

PubMed Search in Google Scholar
37 Kris M G, Natale R B, Herbst R S et al.. A phase II trial of ZD1839 (“Iressa”) in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2) [abstract 1166]. Proc Am Soc Clin Oncol. 2002; 21 292a

PubMed Search in Google Scholar
38 Fukuoka M, Yano S, Giaccone G et al.. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol. 2003; 21 2237-2246

Crossref PubMed Search in Google Scholar
39 Natale R B, Skarin A, Maddox A-M et al.. Improvement in symptoms and quality of life for advanced non-small-cell lung cancer patients receiving ZD1839 (“Iressa”) in IDEAL 2 [abstract 1167]. Proc Am Soc Clin Oncol. 2002; 21 292a

PubMed Search in Google Scholar
40 Douillard J-Y, Giaccone G, Horai T et al.. Improvement in disease-related symptoms and quality of life in patients with advanced non-small cell lung cancer (NSCLC) treated with ZD1839 (“Iressa”) (IDEAL 1) [abstract 1195]. Proc Am Soc Clin Oncol. 2002; 21 299a

PubMed Search in Google Scholar
41 Giaccone G, Johnson D H, Manegold C et al.. A phase III clinical trial of ZD 1839 (“Iressa”) in combination with gemcitabine and cisplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer (INTACT 1). Proc Eur Soc Med Oncol. 2002; 13(suppl 5) S2

PubMed Search in Google Scholar
42 Johnson D H, Herbst R, Giaccone G et al.. ZD 1839 (“Iressa”) in combination with paclitaxel and carboplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer (NSCLC): results from a phase III clinical trial (INTACT 2). Proc Eur Soc Med Oncol. 2002; 13(suppl 5) S127

PubMed Search in Google Scholar
43 Pollack V A, Savage D M, Baker D A et al.. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther. 1999; 291 739-748

PubMed Search in Google Scholar
44 Moyer J D, Barbacci E G, Iwata K K et al.. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 1997; 57 4838-4848

PubMed Search in Google Scholar
45 Budillon A, Di Gennaro E, Barbarino M et al.. ZD 1839, an epidermal growth factor receptor tyrosine kinase inhibitor, upregulates p27^KIP1 inducing G1 arrest and enhancing the antitumor effect of interferon. Proc Am Assoc Cancer Res. 2000; 41 773

PubMed Search in Google Scholar
46 Iliakis G. Cell cycle regulation in irradiated and nonirradiated cells. Semin Oncol. 1997; 24 602-615

PubMed Search in Google Scholar
47 Perez-Soler R, Chachoua A, Huberman M et al.. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC) [abstract 1235]. Proc Am Soc Clin Oncol. 2001; 20 310a

PubMed Search in Google Scholar
48 Lynch D H, Yang X D. Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin Oncol. 2002; 29(suppl 4) S47-S50

PubMed Search in Google Scholar
49 Prewett M, Rockwell P, Rockwell R F et al.. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J Immunother Emphasis Tumor Immunol. 1996; 19 419-427

PubMed Search in Google Scholar
50 Raben D, Helfrich B, Chan D et al.. C225 anti-EGFR antibody potentiates radiation (RT) and chemotherapy (CT) cytotoxicity in human non-small cell lung cancer (NSCLC) cells in vitro and in vivo [abstract 1026]. Proc Am Soc Clin Oncol. 2001; 20 257a

PubMed Search in Google Scholar
51 Baselga J, Pfister D, Cooper M R et al.. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol. 2000; 18 904-914

PubMed Search in Google Scholar
52 Kim E S, Mauer A M, Fossella F V et al.. A phase II study of Erbitux (IMC-225), an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer (NSCLC) [abstract 1168]. Proc Am Soc Clin Oncol. 2002; 21 293a

PubMed Search in Google Scholar
53 Figlin R A, Belldegrun A S, Crawford J et al.. ABX-EGF, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) in patients with advanced cancer: phase I clinical results [abstract 35]. Proc Am Soc Clin Oncol. 2002; 21 10a

PubMed Search in Google Scholar

Joan H SchillerM.D. F.A.C.P.

Comprehensive Cancer Center, University of Wisconsin Hospital and Clinics

600 Highland Ave., Room K4/548, Madison, WI 53792

Email: jhschill@facstaff.wisc.edu